From: Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
Total (n)
DL1 (n)
DL2 (n)
DL3 (n)
n = 20
n = 7
n = 6
Response
Complete Remission
1
0
Partial Remission
14
2
6
Stable Disease
3
Not evaluable